Volume 14, Issue 3, July 2024

Formulation and Evaluation of Medicated Nail Lacquer for the Treatment of Onychomycosis (Research Article)

Author(s): Diptee Marchande, Amisha Vasave, Akshay Waghamare, Shubham Waghmare, Aaditi Wani, Sanjali Yadav, Ashish Jain1
Abstract: Aims: The objective of the research work was to study about medicated antifungal nail lacquer for the treatment of Onychomycosis. Medicated nail lacquers generally act on a principle that it will form a film on the application surface from which the drug is released at a controlled rate for an extended period. Methods: The purpose of the investigation was to formulate and evaluate the Luliconazole nail lacquer as an ungual drug delivery system for the treatment of onychomycosis. Luliconazole an antifungal class of a drug was chosen along with Eudragit RS-100, Ethyl cellulose, Butyl acetate, Urea, Dibutyl phthalate, Methanol. As an excipient Eudragit RS 100 and Ethyl cellulose was used as sustained drug release polymer. Results: Formulation of nail lacquer done with taking different % of excipients. Further, these lacquers were compared for drying time, nonvolatile content drug content, drug diffusion and anti -microbial studies. Out of all 5 formulations F2 was considered as the optimized formulation. The stability studies show that the formulation is stable at 40 C for 15 days. F2 Formulation showed 98.5% drug content and 45 mm zone of inhibition which is greater compared to other formulations. So, a good therapeutic outcome can be expected. Microbial study results proved that the formulations are sensitive to the Candida albicans. Conclusion: So, from the above studies it can be concluded that an nail lacquer can be a better tool for ungal drug delivery system for the treatment of nail infection, onychomycosis.
PAGES: 26-34  |  332 VIEWS  303 DOWNLOADS

How To Cite this Article:

Diptee Marchande, Amisha Vasave, Akshay Waghamare, Shubham Waghmare, Aaditi Wani, Sanjali Yadav, Ashish Jain1. Formulation and Evaluation of Medicated Nail Lacquer for the Treatment of Onychomycosis (Research Article). 2024; 14(3): 26-34.